Combination chemotherapy in the treatment of advanced Hodgkin's disease.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*; D011344:Procarbazine / Q000009:adverse effects / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D014747:Vinblastine / Q000009:adverse effects / Q000627:therapeutic use*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001565:Benzoates; D009588:Nitrogen Mustard Compounds; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D011241:Prednisone